Endpoints News

Endpoints News The biopharma world is here. Endpoints News is an independent news organization, reporting on the top global biotech & pharmaceutical R&D news of the day.

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies
05/20/2024

Exclusive: Members of Congress buy and sell stocks that would gain from bill banning China biotech companies

At least seven members of Congress since 2023 have bought and sold stocks of life science companies that would gain from legislation to ban several key Chinese biotech suppliers and contractors, according to financial disclosures. The Biosecure Act, which advanced in the House last week, would force...

Senior Biopharma Correspondent Andrew Dunn sat down (virtually) with biotech's Renaissance man, Siddhartha Mukherjee, in...
05/14/2024

Senior Biopharma Correspondent Andrew Dunn sat down (virtually) with biotech's Renaissance man, Siddhartha Mukherjee, in the latest Endpoints Slack Interview. They talked about AI, Mukherjee's slew of ambitious biotech startups, and how he got into writing epic, Pulitzer-winning tomes on medicine and science.

Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him in many directions, including running a research lab at Columbia University, co-founding a growing list of biotech startups, and writing books on s...

Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study i...
05/13/2024

Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes.

Novo Nordisk said Monday that its investigational treatment met both primary endpoints in an open-label Phase 3a study in patients with hemophilia A, meaning patients had fewer bleeding episodes. Following the topline FRONTIER 2 data disclosure via a press release, the Danish drugmaker's shares $NVO...

Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according...
05/09/2024

Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday.

BALTIMORE — Ten out of 11 children who were born deaf can now hear after receiving a gene therapy from a Shanghai biotech, according to new results shared Thursday. The children who recovered their hearing are also showing improvements in their ability to speak. Some are saying the words “mama.....

For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the m...
05/08/2024

For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the market felt unimpeachable, with AbbVie’s Humira retaining 96% of the share by February. That changed when Humira came off the formulary of CVS Health’s pharmacy benefit manager Caremark.

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) For the first time in April, biosimilars started to gain a larger share of the Humira market. Up until that point, the market felt unimpeachable, with AbbVie's Humira retaining 96% of the

A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the ...
05/07/2024

A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed.

A Duchenne muscular dystrophy patient died of cardiac arrest on Friday in a Phase 2 trial of Pfizer’s gene therapy, the pharma company confirmed. The patient received fordadistrogene movaparvovec in early 2023 as part of Pfizer’s DAYLIGHT study enrolling patients 2 and 3 years old. As a result o...

The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday...
05/06/2024

The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday, some of which would affect how the next round of drug prices is negotiated under the Inflation Reduction Act. On Monday, industry groups PhRMA and BIO raised new concerns about the guidance.

The Centers for Medicare & Medicaid Services proposed a number of changes to its Medicare negotiation guidance on Friday, some of which would affect how the next round of drug prices is negotiated under the Inflation Reduction Act. On Monday, industry groups PhRMA and BIO raised new concerns about t...

AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany ...
05/03/2024

AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week.

AbbVie is investing around €150 million ($161 million) into an R&D site at its Rhineland-Palatinate location in Germany which it expects to complete in 2027, the company announced this week. At a site that employs more than 2,000 already, the new building will house more than 300 employees in onco...

Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bris...
05/02/2024

Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on business in first-quarter earnings calls.

Despite the pharmaceutical industry’s heavy criticism of the Inflation Reduction Act, Johnson & Johnson, Pfizer and Bristol Myers Squibb recently downplayed the legislation’s overall impact on business in first-quarter earnings calls. All three companies voiced early opposition to the IRA, liken...

Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Healt...
04/26/2024

Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health Organization-led global pandemic preparedness agreement that’s nearing completion.

Sen. Bernie Sanders (I-VT) is calling on global pharmaceutical leaders to get behind proposals laid out in a World Health Organization-led global pandemic preparedness agreement that's nearing completion. On Thursday, Sanders wrote to the International Federation of Pharmaceutical Manufacturers and....

GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against th...
04/25/2024

GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners.

GSK says it is owed a portion of Pfizer and BioNTech’s Covid-19 vaccine sales in the latest patent suit filed against the Comirnaty partners. In a lawsuit filed in federal court in Delaware Thursday, the UK pharma claimed Pfizer and BioNTech benefited from mRNA research conducted more than a decad...

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in Chin...
04/24/2024

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets.

Roche on Wednesday morning said it has “minor exposure” from the Biosecure Act, adding that it is making strides in China’s pharma and diagnostics markets. “We’ve really worked on diversifying our supply chain and this is helping us now, so that we have multiple partners to work with acros...

Address

Lawrence, KS

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+17858131733

Alerts

Be the first to know and let us send you an email when Endpoints News posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Share